首页 > 最新文献

Livers最新文献

英文 中文
Bio-Artificial Liver Support System: A Prospective Future Therapy 生物人工肝支持系统:一种前瞻性的未来治疗方法
Pub Date : 2023-02-09 DOI: 10.3390/livers3010006
C. Jasirwan, A. Muradi, R. Antarianto
Whether acute or chronic, liver failure is a state of liver dysfunction that can progress to multiorgan failure. Mortality in liver failure patients is approximately 80–90% and is caused by detoxification failure, which triggers other immediate complications, such as encephalopathy, coagulopathy, jaundice, cholestasis, and acute kidney failure. The ideal treatment for liver failure is liver transplantation, but the long waiting period for the right donor match causes unavoidable deaths in most patients. Therefore, new therapies, such as tissue engineering, hepatocyte transplantation, and stem cells, are now being studied to anticipate the patient’s condition while waiting for liver transplantation. This literature review investigated the effectiveness of some bio-artificial liver support systems using review methods systematically from international publication sites, including PubMed, using keywords, such as bio-artificial liver, acute and chronic liver failure, extracorporeal liver support system (ECLS), MARS, single-pass albumin dialysis (SPAD). Artificial and bioartificial liver systems can show specific detoxification abilities and pathophysiological improvements in liver failure patients but cannot reach the ideal criteria for actual liver function. The liver support system must provide the metabolic and synthetic function as in the actual liver while reducing the pathophysiological changes in liver failure. Aspects of safety, cost efficiency, and practicality are also considered. Identifying the technology to produce high-quality hepatocytes on a big scale is essential as a medium to replace failing liver cells. An increase in detoxification capacity and therapeutic effectiveness must also focus on patient survival and the ability to perform liver transplantation.
无论是急性还是慢性,肝衰竭都是一种肝功能障碍状态,可发展为多器官衰竭。肝衰竭患者的死亡率约为80-90%,是由解毒失败引起的,这会引发其他直接并发症,如脑病、凝血障碍、黄疸、胆汁淤积和急性肾衰竭。肝衰竭的理想治疗方法是肝移植,但长期等待合适的供体匹配会导致大多数患者不可避免的死亡。因此,目前正在研究新的治疗方法,如组织工程、肝细胞移植和干细胞,以预测患者在等待肝移植时的病情。这篇文献综述使用国际出版物网站(包括PubMed)的综述方法,系统地研究了一些生物人工肝支持系统的有效性,使用了关键词,如生物人工肝、急性和慢性肝衰竭、体外肝支持系统(ECLS)、MARS、单程白蛋白透析(SPAD)。人工和生物人工肝系统可以在肝衰竭患者中显示出特定的解毒能力和病理生理学改善,但不能达到实际肝功能的理想标准。肝脏支持系统必须提供与实际肝脏一样的代谢和合成功能,同时减少肝衰竭的病理生理变化。还考虑了安全性、成本效益和实用性方面的问题。确定大规模生产高质量肝细胞的技术,作为替代衰竭肝细胞的培养基至关重要。提高解毒能力和治疗效果还必须关注患者的生存率和进行肝移植的能力。
{"title":"Bio-Artificial Liver Support System: A Prospective Future Therapy","authors":"C. Jasirwan, A. Muradi, R. Antarianto","doi":"10.3390/livers3010006","DOIUrl":"https://doi.org/10.3390/livers3010006","url":null,"abstract":"Whether acute or chronic, liver failure is a state of liver dysfunction that can progress to multiorgan failure. Mortality in liver failure patients is approximately 80–90% and is caused by detoxification failure, which triggers other immediate complications, such as encephalopathy, coagulopathy, jaundice, cholestasis, and acute kidney failure. The ideal treatment for liver failure is liver transplantation, but the long waiting period for the right donor match causes unavoidable deaths in most patients. Therefore, new therapies, such as tissue engineering, hepatocyte transplantation, and stem cells, are now being studied to anticipate the patient’s condition while waiting for liver transplantation. This literature review investigated the effectiveness of some bio-artificial liver support systems using review methods systematically from international publication sites, including PubMed, using keywords, such as bio-artificial liver, acute and chronic liver failure, extracorporeal liver support system (ECLS), MARS, single-pass albumin dialysis (SPAD). Artificial and bioartificial liver systems can show specific detoxification abilities and pathophysiological improvements in liver failure patients but cannot reach the ideal criteria for actual liver function. The liver support system must provide the metabolic and synthetic function as in the actual liver while reducing the pathophysiological changes in liver failure. Aspects of safety, cost efficiency, and practicality are also considered. Identifying the technology to produce high-quality hepatocytes on a big scale is essential as a medium to replace failing liver cells. An increase in detoxification capacity and therapeutic effectiveness must also focus on patient survival and the ability to perform liver transplantation.","PeriodicalId":74083,"journal":{"name":"Livers","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49607034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Acknowledgment to the Reviewers of Livers in 2022 对2022年《肝脏》评审者的感谢
Pub Date : 2023-01-19 DOI: 10.3390/livers3010005
High-quality academic publishing is built on rigorous peer review [...]
高质量的学术出版建立在严格的同行评审基础上〔…〕
{"title":"Acknowledgment to the Reviewers of Livers in 2022","authors":"","doi":"10.3390/livers3010005","DOIUrl":"https://doi.org/10.3390/livers3010005","url":null,"abstract":"High-quality academic publishing is built on rigorous peer review [...]","PeriodicalId":74083,"journal":{"name":"Livers","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44299171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lights and Shadows of Paracentesis: Is an Ultrasound Guided Approach Enough to Prevent Bleeding Complications? 穿刺的光影:超声引导的方法足以预防出血并发症吗?
Pub Date : 2023-01-16 DOI: 10.3390/livers3010004
M. Patturelli, L. Pignata, P. Venetucci, M. Guarino
Paracentesis is a validated procedure for diagnosing and managing ascites. Although paracentesis is a safe procedure with a 1–2% risk of complications such as bleeding, it is necessary to inform the patient about the possible adverse events. We would like to share our experience with two cases of bleeding after paracentesis. In our unit, two major hemorrhagic complications occurred in 162 procedures performed over the year 2020 (frequency of bleeding complications: 1.2%). We report two clinical cases of post-paracentesis abdominal wall hematomas. Despite a similar clinical presentation, the management approach was different: in the first case, embolization of the epigastric artery supplying the hematoma was performed. In the second case, conservative treatment was adopted. Our report aims to provide food for thought about a potentially challenging hemorrhagic complication, even with the risk of adverse outcomes.
穿刺术是诊断和处理腹水的有效方法。虽然穿刺术是一种安全的手术,有1-2%的并发症风险,如出血,但有必要告知患者可能发生的不良事件。我们想分享两例穿刺后出血的经验。在我们单位,在2020年进行的162例手术中发生了两种主要的出血性并发症(出血并发症的频率:1.2%)。我们报告两例穿刺后腹壁血肿的临床病例。尽管临床表现相似,但治疗方法不同:在第一例中,对供应血肿的腹壁动脉进行栓塞。第二例采用保守治疗。我们的报告旨在为考虑潜在的具有挑战性的出血性并发症提供食物,即使有不良后果的风险。
{"title":"Lights and Shadows of Paracentesis: Is an Ultrasound Guided Approach Enough to Prevent Bleeding Complications?","authors":"M. Patturelli, L. Pignata, P. Venetucci, M. Guarino","doi":"10.3390/livers3010004","DOIUrl":"https://doi.org/10.3390/livers3010004","url":null,"abstract":"Paracentesis is a validated procedure for diagnosing and managing ascites. Although paracentesis is a safe procedure with a 1–2% risk of complications such as bleeding, it is necessary to inform the patient about the possible adverse events. We would like to share our experience with two cases of bleeding after paracentesis. In our unit, two major hemorrhagic complications occurred in 162 procedures performed over the year 2020 (frequency of bleeding complications: 1.2%). We report two clinical cases of post-paracentesis abdominal wall hematomas. Despite a similar clinical presentation, the management approach was different: in the first case, embolization of the epigastric artery supplying the hematoma was performed. In the second case, conservative treatment was adopted. Our report aims to provide food for thought about a potentially challenging hemorrhagic complication, even with the risk of adverse outcomes.","PeriodicalId":74083,"journal":{"name":"Livers","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47823966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic Associated Fatty Liver Disease as a Risk Factor for the Development of Central Nervous System Disorders 代谢相关脂肪肝是中枢神经系统疾病发展的危险因素
Pub Date : 2023-01-05 DOI: 10.3390/livers3010002
Sayuri Yoshikawa, Kurumi Taniguchi, Haruka Sawamura, Yuka Ikeda, Tomoko Asai, Ai Tsuji, Satoru Matsuda
MAFLD/NAFLD is the most ordinary liver disease categorized by hepatic steatosis with the increase of surplus fat in the liver and metabolic liver dysfunction, which is associated with bigger mortality and a high medical burden. An association between MAFLD/NAFLD and central nervous system disorders including psychological disorders has been demonstrated. Additionally, MAFLD/NAFLD has been correlated with various types of neurodegenerative disorders such as amyotrophic lateral sclerosis or Parkinson’s disease. Contrasted to healthy controls, patients with MAFLD/NAFLD have a greater prevalence risk of extrahepatic complications within multiple organs. Dietary interventions have emerged as effective strategies for MAFLD/NAFLD. The PI3K/AKT/mTOR signaling pathway involved in the regulation of Th17/Treg balance might promote the pathogenesis of several diseases including MAFLD/NAFLD. As extrahepatic complications may happen across various organs including CNS, cooperative care with individual experts is also necessary for managing patients with MAFLD/NAFLD.
MAFLD/NAFLD是最常见的肝脏疾病,以肝脏脂肪变性为分类,伴有肝脏多余脂肪增加和代谢性肝功能障碍,死亡率较高,医疗负担较高。NAFLD与中枢神经系统疾病(包括心理障碍)之间的关联已得到证实。此外,MAFLD/NAFLD与各种类型的神经退行性疾病,如肌萎缩侧索硬化症或帕金森病相关。与健康对照相比,MAFLD/NAFLD患者在多器官内出现肝外并发症的风险更高。饮食干预已成为治疗mald /NAFLD的有效策略。参与调节Th17/Treg平衡的PI3K/AKT/mTOR信号通路可能促进包括MAFLD/NAFLD在内的多种疾病的发病机制。由于肝外并发症可能发生在包括中枢神经系统在内的各个器官,因此在治疗MAFLD/NAFLD患者时,与个别专家的合作护理也是必要的。
{"title":"Metabolic Associated Fatty Liver Disease as a Risk Factor for the Development of Central Nervous System Disorders","authors":"Sayuri Yoshikawa, Kurumi Taniguchi, Haruka Sawamura, Yuka Ikeda, Tomoko Asai, Ai Tsuji, Satoru Matsuda","doi":"10.3390/livers3010002","DOIUrl":"https://doi.org/10.3390/livers3010002","url":null,"abstract":"MAFLD/NAFLD is the most ordinary liver disease categorized by hepatic steatosis with the increase of surplus fat in the liver and metabolic liver dysfunction, which is associated with bigger mortality and a high medical burden. An association between MAFLD/NAFLD and central nervous system disorders including psychological disorders has been demonstrated. Additionally, MAFLD/NAFLD has been correlated with various types of neurodegenerative disorders such as amyotrophic lateral sclerosis or Parkinson’s disease. Contrasted to healthy controls, patients with MAFLD/NAFLD have a greater prevalence risk of extrahepatic complications within multiple organs. Dietary interventions have emerged as effective strategies for MAFLD/NAFLD. The PI3K/AKT/mTOR signaling pathway involved in the regulation of Th17/Treg balance might promote the pathogenesis of several diseases including MAFLD/NAFLD. As extrahepatic complications may happen across various organs including CNS, cooperative care with individual experts is also necessary for managing patients with MAFLD/NAFLD.","PeriodicalId":74083,"journal":{"name":"Livers","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41713611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Support Needs and Coping Strategies in Non-Alcoholic Fatty Liver Disease (NAFLD): A Multidisciplinary Approach to Potential Unmet Challenges beyond Pharmacological Treatment 非酒精性脂肪性肝病(NAFLD)的支持需求和应对策略:药物治疗之外潜在未满足挑战的多学科方法
Pub Date : 2022-12-23 DOI: 10.3390/livers3010001
S. Shea, C. Lionis, L. Atkinson, C. Kite, Lukasz Lagojda, Surinderjeet S. Chaggar, I. Kyrou, H. Randeva
Non-alcoholic fatty liver disease (NAFLD) is the most frequently occurring chronic liver disease, affecting approximately 25–30% of the adult general population worldwide. NAFLD reflects excess hepatic accumulation of fat in the absence of increased alcohol intake, and, due to its close association with obesity, is frequently referred to as the ‘hepatic manifestation’ of metabolic syndrome. Indeed, a high percentage of individuals with NAFLD present with a combination of the cardio-metabolic comorbidities that are associated with the metabolic syndrome. In addition to its well-established link with the metabolic syndrome and increased risk for cardiovascular disease, NAFLD has also been associated with certain mental health issues (e.g., depression and stress). Although this link is now being increasingly recognized, there are still unmet needs regarding the holistic management of patients with NAFLD, which could further contribute to feelings of social isolation and loneliness. The latter conditions are also increasingly reported to pose a substantial risk to overall health and quality of life. To date, there is limited research that has explored these issues among patients with NAFLD, despite existing data which indicate that perceived loneliness and isolation may pose an additional health risk. Notably, many features associated with NAFLD have been related to these concepts, such as perceived stigma, fatigue, stress, and confusion regarding this diagnosis. As such, this review aimed to assess such potential problems faced by patients with NAFLD, and to explore the possibility of unmet support needs which could lead to perceived social isolation. Moreover, the importance of a compassionate approach towards such patients is discussed, together with potential coping strategies. Future research directions and the need for a multidisciplinary approach are also highlighted.
非酒精性脂肪性肝病(NAFLD)是最常见的慢性肝病,影响全球约25-30%的成年普通人群。NAFLD反映了在没有增加酒精摄入的情况下肝脏脂肪的过度积累,并且由于其与肥胖密切相关,通常被称为代谢综合征的“肝脏表现”。事实上,有很高比例的NAFLD患者存在与代谢综合征相关的心代谢合并症。NAFLD除了与代谢综合征和心血管疾病风险增加有明确的联系外,还与某些心理健康问题(如抑郁和压力)有关。虽然这种联系现在越来越被认识到,但在NAFLD患者的整体管理方面仍然存在未满足的需求,这可能进一步导致社会孤立和孤独感。据报道,后一种情况也越来越多地对整体健康和生活质量构成重大风险。迄今为止,在NAFLD患者中探索这些问题的研究有限,尽管现有数据表明,感知到的孤独和孤立可能会造成额外的健康风险。值得注意的是,与NAFLD相关的许多特征都与这些概念有关,例如感知到的耻辱感、疲劳、压力和对这种诊断的困惑。因此,本综述旨在评估NAFLD患者面临的这些潜在问题,并探讨未满足的支持需求可能导致感知到的社会孤立的可能性。此外,讨论了对此类患者采取富有同情心的方法的重要性,以及潜在的应对策略。指出了未来的研究方向和多学科方法的必要性。
{"title":"Support Needs and Coping Strategies in Non-Alcoholic Fatty Liver Disease (NAFLD): A Multidisciplinary Approach to Potential Unmet Challenges beyond Pharmacological Treatment","authors":"S. Shea, C. Lionis, L. Atkinson, C. Kite, Lukasz Lagojda, Surinderjeet S. Chaggar, I. Kyrou, H. Randeva","doi":"10.3390/livers3010001","DOIUrl":"https://doi.org/10.3390/livers3010001","url":null,"abstract":"Non-alcoholic fatty liver disease (NAFLD) is the most frequently occurring chronic liver disease, affecting approximately 25–30% of the adult general population worldwide. NAFLD reflects excess hepatic accumulation of fat in the absence of increased alcohol intake, and, due to its close association with obesity, is frequently referred to as the ‘hepatic manifestation’ of metabolic syndrome. Indeed, a high percentage of individuals with NAFLD present with a combination of the cardio-metabolic comorbidities that are associated with the metabolic syndrome. In addition to its well-established link with the metabolic syndrome and increased risk for cardiovascular disease, NAFLD has also been associated with certain mental health issues (e.g., depression and stress). Although this link is now being increasingly recognized, there are still unmet needs regarding the holistic management of patients with NAFLD, which could further contribute to feelings of social isolation and loneliness. The latter conditions are also increasingly reported to pose a substantial risk to overall health and quality of life. To date, there is limited research that has explored these issues among patients with NAFLD, despite existing data which indicate that perceived loneliness and isolation may pose an additional health risk. Notably, many features associated with NAFLD have been related to these concepts, such as perceived stigma, fatigue, stress, and confusion regarding this diagnosis. As such, this review aimed to assess such potential problems faced by patients with NAFLD, and to explore the possibility of unmet support needs which could lead to perceived social isolation. Moreover, the importance of a compassionate approach towards such patients is discussed, together with potential coping strategies. Future research directions and the need for a multidisciplinary approach are also highlighted.","PeriodicalId":74083,"journal":{"name":"Livers","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43905477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
A Simple Algorithm for Semiquantitative Analysis of Scored Histology Data in the R Environment, on the Example of Murine Non-Alcoholic Steatohepatitis Pharmacotherapy 一种在R环境中对评分组织学数据进行半定量分析的简单算法,以小鼠非酒精性脂肪性肝炎药物治疗为例
Pub Date : 2022-12-09 DOI: 10.3390/livers2040031
V. Prikhodko, V. Karev, Yuriy I. Sysoev, D. Ivkin, S. Okovityi
Despite the high medical and socioeconomic burden of non-alcoholic fatty liver disease (NAFLD), treatments that could effectively reduce histological liver damage in this condition are lacking. As providing only qualitative data is a major limitation of most histological scoring systems, we aimed to develop a simple and straightforward algorithm for semiquantitative analysis of scored histology data using the extended Fisher’s exact test in the R environment. As an illustrative example, we used the effects of L-ornithine L-aspartate (LOLA) and empagliflozin (EMPA) in a 3-month chemical/dietary murine model of NAFLD. 100 C57Bl/6 mice were randomized into 4 groups: Intact (n = 10), Control (NAFLD; n = 30), LOLA (NAFLD + 1.5 g·kg−1 b.w./d LOLA orally; n = 30), and EMPA (NAFLD + 10 mg·kg−1 b.w./d EMPA orally; n = 30). LOLA reduced hepatitis activity (p < 0.05), cholestasis, necrosis, and fibrosis severity (p < 0.01), and EMPA prevented necrosis (p < 0.05) and reduced fibrosis severity (p < 0.01). The statistical approach we suggest can be used as a simple complementary tool for exploratory analysis of scored histology data.
尽管非酒精性脂肪性肝病(NAFLD)的医疗和社会经济负担很高,但缺乏能够有效减少这种情况下组织学肝损伤的治疗方法。由于仅提供定性数据是大多数组织学评分系统的主要限制,我们旨在开发一种简单直接的算法,在R环境中使用扩展的Fisher精确检验对评分的组织学数据进行半定量分析。作为一个说明性的例子,我们在一个3个月的NAFLD化学/饮食小鼠模型中使用了L-天冬氨酸鸟氨酸(LOLA)和恩帕列嗪(EMPA)的作用。将100只C57Bl/6小鼠随机分为4组:完整组(n=10)、对照组(NAFLD;n=30)、LOLA(NAFLD+1.5 g·kg−1 b.w./d口服LOLA;n=30。LOLA降低了肝炎活性(p<0.05)、胆汁淤积、坏死和纤维化严重程度(p<0.01),EMPA预防了坏死(p<0.05)并降低了纤维化严重程度。我们建议的统计方法可以作为一种简单的补充工具,用于对评分的组织学数据进行探索性分析。
{"title":"A Simple Algorithm for Semiquantitative Analysis of Scored Histology Data in the R Environment, on the Example of Murine Non-Alcoholic Steatohepatitis Pharmacotherapy","authors":"V. Prikhodko, V. Karev, Yuriy I. Sysoev, D. Ivkin, S. Okovityi","doi":"10.3390/livers2040031","DOIUrl":"https://doi.org/10.3390/livers2040031","url":null,"abstract":"Despite the high medical and socioeconomic burden of non-alcoholic fatty liver disease (NAFLD), treatments that could effectively reduce histological liver damage in this condition are lacking. As providing only qualitative data is a major limitation of most histological scoring systems, we aimed to develop a simple and straightforward algorithm for semiquantitative analysis of scored histology data using the extended Fisher’s exact test in the R environment. As an illustrative example, we used the effects of L-ornithine L-aspartate (LOLA) and empagliflozin (EMPA) in a 3-month chemical/dietary murine model of NAFLD. 100 C57Bl/6 mice were randomized into 4 groups: Intact (n = 10), Control (NAFLD; n = 30), LOLA (NAFLD + 1.5 g·kg−1 b.w./d LOLA orally; n = 30), and EMPA (NAFLD + 10 mg·kg−1 b.w./d EMPA orally; n = 30). LOLA reduced hepatitis activity (p < 0.05), cholestasis, necrosis, and fibrosis severity (p < 0.01), and EMPA prevented necrosis (p < 0.05) and reduced fibrosis severity (p < 0.01). The statistical approach we suggest can be used as a simple complementary tool for exploratory analysis of scored histology data.","PeriodicalId":74083,"journal":{"name":"Livers","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42242241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
One Carbon Metabolism and S-Adenosylmethionine in Non-Alcoholic Fatty Liver Disease Pathogenesis and Subtypes. 1碳代谢和s -腺苷蛋氨酸在非酒精性脂肪肝发病机制和亚型中的作用。
Pub Date : 2022-12-01 DOI: 10.3390/livers2040020
David Fernández-Ramos, Fernando Lopitz-Otsoa, Oscar Millet, Cristina Alonso, Shelly C Lu, José M Mato

One carbon metabolism (1CM) can be defined as the transfer of a carbon unit from one metabolite to another and its replenishment by different sources of labile methyl-group nutrients: primarily choline, methionine, betaine, and serine. This flow of carbon units allows the biosynthesis of nucleotides, amino acids, formylated methionyl-tRNA, polyamines, glutathione, phospholipids, detoxification reactions, maintenance of the redox status and the concentration of NAD, and methylation reactions including epigenetic modifications. That is, 1CM functions as a nutrient sensor and integrator of cellular metabolism. A critical process in 1CM is the synthesis of S-adenosylmethionine (SAMe), the source of essentially all the hundreds of millions of daily methyl transfer reactions in a cell. This versatility of SAMe imposes a tight control in its synthesis and catabolism. Much of our knowledge concerning 1CM has been gained from studies in the production and prevention of nonalcoholic fatty liver disease (NAFLD). Here, we discuss in detail the function of the most important enzymes for their quantitative contribution to maintaining the flux of carbon units through 1CM in the liver and discuss how alterations in their enzymatic activity contribute to the development of NAFLD. Next, we discuss NAFLD subtypes based on serum lipidomic profiles with different risk of cardiovascular disease. Among the latter, we highlight the so-called subtype A for its serum lipidomic profile phenocopying that of mice deficient in SAMe synthesis and because its high frequency (about 50% of the NAFLD patients).

一次碳代谢(1CM)可以定义为碳单位从一种代谢物转移到另一种代谢物,并通过不同来源的不稳定甲基营养素(主要是胆碱、蛋氨酸、甜菜碱和丝氨酸)进行补充。碳单元的流动允许核苷酸、氨基酸、甲酰化甲硫基trna、多胺、谷胱甘肽、磷脂的生物合成、解毒反应、氧化还原状态和NAD浓度的维持,以及包括表观遗传修饰的甲基化反应。也就是说,1CM作为细胞代谢的营养传感器和积分器。1CM中的一个关键过程是s -腺苷甲硫氨酸(SAMe)的合成,这是细胞中每天数亿个甲基转移反应的基本来源。SAMe的这种多功能性对其合成和分解代谢施加了严格的控制。我们关于1CM的大部分知识都是从非酒精性脂肪性肝病(NAFLD)的产生和预防研究中获得的。在这里,我们详细讨论了最重要的酶的功能,因为它们对维持肝脏中碳单位通过1CM的通量的定量贡献,并讨论了它们的酶活性的改变如何促进NAFLD的发展。接下来,我们讨论基于血清脂质组学特征的NAFLD亚型与不同心血管疾病风险。在后者中,我们强调了所谓的A亚型,因为它的血清脂质组学特征与SAMe合成缺陷小鼠的表型相似,并且因为它的高频率(约占NAFLD患者的50%)。
{"title":"One Carbon Metabolism and <i>S</i>-Adenosylmethionine in Non-Alcoholic Fatty Liver Disease Pathogenesis and Subtypes.","authors":"David Fernández-Ramos,&nbsp;Fernando Lopitz-Otsoa,&nbsp;Oscar Millet,&nbsp;Cristina Alonso,&nbsp;Shelly C Lu,&nbsp;José M Mato","doi":"10.3390/livers2040020","DOIUrl":"https://doi.org/10.3390/livers2040020","url":null,"abstract":"<p><p>One carbon metabolism (1CM) can be defined as the transfer of a carbon unit from one metabolite to another and its replenishment by different sources of labile methyl-group nutrients: primarily choline, methionine, betaine, and serine. This flow of carbon units allows the biosynthesis of nucleotides, amino acids, formylated methionyl-tRNA, polyamines, glutathione, phospholipids, detoxification reactions, maintenance of the redox status and the concentration of NAD, and methylation reactions including epigenetic modifications. That is, 1CM functions as a nutrient sensor and integrator of cellular metabolism. A critical process in 1CM is the synthesis of <i>S</i>-adenosylmethionine (SAMe), the source of essentially all the hundreds of millions of daily methyl transfer reactions in a cell. This versatility of SAMe imposes a tight control in its synthesis and catabolism. Much of our knowledge concerning 1CM has been gained from studies in the production and prevention of nonalcoholic fatty liver disease (NAFLD). Here, we discuss in detail the function of the most important enzymes for their quantitative contribution to maintaining the flux of carbon units through 1CM in the liver and discuss how alterations in their enzymatic activity contribute to the development of NAFLD. Next, we discuss NAFLD subtypes based on serum lipidomic profiles with different risk of cardiovascular disease. Among the latter, we highlight the so-called subtype A for its serum lipidomic profile phenocopying that of mice deficient in SAMe synthesis and because its high frequency (about 50% of the NAFLD patients).</p>","PeriodicalId":74083,"journal":{"name":"Livers","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137169/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9751790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Anti-Metastatic Activity of Tagitinin C from Tithonia diversifolia in a Xenograft Mouse Model of Hepatocellular Carcinoma 鬼针草Tagitinin C在肝癌异种移植小鼠模型中的抗转移活性
Pub Date : 2022-12-01 DOI: 10.3390/livers2040030
Chuan-Yi Lin, May-Hua Liao, Chi-Yu Yang, Chao-Kai Chang, Shih-Mei Hsu, C. Juang, H. Wen
Sesquiterpenoid tagitinin C, present in Tithonia diversifolia leaves, has been known to have anti-hepatoma properties. Therefore, we investigated the anti-metastatic potential of tagitinin C in xenograft models of hepatocellular carcinoma (HCC). We isolated tagitinin C from a methanolic extract of the leaves of T. diversifolia. HepG-2 and Huh 7 hepatoma cells were treated with tagitinin C, and cell viability, migration, and matrix metalloproteinase (MPP) activity were assessed using the 3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide assay, scratch migration assay, and MMP activity assay, respectively. We used magnetic resonance spectroscopy to determine the tumorigenicity of xenografts inoculated with Hep-G2 and Huh 7 cells. Tagitinin C was cytotoxic against Hep-G2 and Huh 7 cells, with IC50 values of 2.0 ± 0.1 µg/mL and 1.2 ± 0.1 µg/mL, respectively, and it showed an anti-metastatic effect in vitro. Additionally, MRS assays revealed that tagitinin C (15 g/mouse/day) reduced the tumorigenicity of Hep-G2 and Huh 7 cell xenografts. Tagitinin C demonstrated significant antitumor and anti-metastatic activity in the two human hepatoma cell lines. Tagitinin C might be used as an alternative or auxiliary therapy for the treatment of HCC, and its effect should be further investigated in clinical settings.
千叶香叶中存在的倍半萜类tagitinin C具有抗肝癌的特性。因此,我们研究了tagitinin C在肝细胞癌(HCC)异种移植模型中的抗转移潜力。我们从三叶草(T.diversifolia)叶的甲醇提取物中分离出tagitinin C。用tagitininC处理HepG-2和Huh7肝癌细胞,并分别用3-(4,5-二甲基硫唑-2-基)-2,5-二苯基溴化四氮唑测定法、划痕迁移测定法和MMP活性测定法评估细胞活力、迁移和基质金属蛋白酶(MPP)活性。我们使用磁共振波谱来确定接种Hep-G2和Huh7细胞的异种移植物的致瘤性。Tagitinin C对Hep-G2和Huh 7细胞具有细胞毒性,IC50值分别为2.0±0.1µg/mL和1.2±0.1µg/mL,在体外显示出抗转移作用。此外,MRS测定显示,tagitinin C(15g/小鼠/天)降低了Hep-G2和Huh 7细胞异种移植物的致瘤性。Tagitinin C在两种人肝癌细胞系中显示出显著的抗肿瘤和抗转移活性。Tagitinin C可能被用作HCC的替代或辅助治疗,其效果应在临床环境中进一步研究。
{"title":"Anti-Metastatic Activity of Tagitinin C from Tithonia diversifolia in a Xenograft Mouse Model of Hepatocellular Carcinoma","authors":"Chuan-Yi Lin, May-Hua Liao, Chi-Yu Yang, Chao-Kai Chang, Shih-Mei Hsu, C. Juang, H. Wen","doi":"10.3390/livers2040030","DOIUrl":"https://doi.org/10.3390/livers2040030","url":null,"abstract":"Sesquiterpenoid tagitinin C, present in Tithonia diversifolia leaves, has been known to have anti-hepatoma properties. Therefore, we investigated the anti-metastatic potential of tagitinin C in xenograft models of hepatocellular carcinoma (HCC). We isolated tagitinin C from a methanolic extract of the leaves of T. diversifolia. HepG-2 and Huh 7 hepatoma cells were treated with tagitinin C, and cell viability, migration, and matrix metalloproteinase (MPP) activity were assessed using the 3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide assay, scratch migration assay, and MMP activity assay, respectively. We used magnetic resonance spectroscopy to determine the tumorigenicity of xenografts inoculated with Hep-G2 and Huh 7 cells. Tagitinin C was cytotoxic against Hep-G2 and Huh 7 cells, with IC50 values of 2.0 ± 0.1 µg/mL and 1.2 ± 0.1 µg/mL, respectively, and it showed an anti-metastatic effect in vitro. Additionally, MRS assays revealed that tagitinin C (15 g/mouse/day) reduced the tumorigenicity of Hep-G2 and Huh 7 cell xenografts. Tagitinin C demonstrated significant antitumor and anti-metastatic activity in the two human hepatoma cell lines. Tagitinin C might be used as an alternative or auxiliary therapy for the treatment of HCC, and its effect should be further investigated in clinical settings.","PeriodicalId":74083,"journal":{"name":"Livers","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41611491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Role of Pyroptosis in Acetaminophen-Induced Hepatotoxicity. 对乙酰氨基酚诱导的肝毒性中的热蛋白沉积作用
Pub Date : 2022-12-01 Epub Date: 2022-12-13 DOI: 10.3390/livers2040032
Hartmut Jaeschke, David S Umbaugh, Anup Ramachandran

Acetaminophen (APAP) is a widely used pain reliever that can cause liver injury or liver failure in response to an overdose. Understanding the mechanisms of APAP-induced cell death is critical for identifying new therapeutic targets. In this respect it was hypothesized that hepatocytes die by oncotic necrosis, apoptosis, necroptosis, ferroptosis and more recently pyroptosis. The latter cell death is characterized by caspase-dependent gasdermin cleavage into a C-terminal and an N-terminal fragment, which forms pores in the plasma membrane. The gasdermin pores can release potassium, interleukin-1β (IL-1β), IL-18, and other small molecules in a sublytic phase, which can be the main function of the pores in certain cell types such as inflammatory cells. Alternatively, the process can progress to full lysis of the cell (pyroptosis) with extensive cell contents release. This review discusses the experimental evidence for the involvement of pyroptosis in APAP hepatotoxicity as well as the arguments against pyroptosis as a relevant mechanism of APAP-induced cell death in hepatocytes. Based on the critical evaluation of the currently available literature and understanding of the pathophysiology, it can be concluded that pyroptotic cell death is unlikely to be a relevant contributor to APAP-induced liver injury.

对乙酰氨基酚(APAP)是一种广泛使用的止痛药,过量服用可导致肝损伤或肝衰竭。了解 APAP 诱导细胞死亡的机制对于确定新的治疗靶点至关重要。在这方面,有人假设肝细胞会通过肿瘤性坏死、凋亡、坏死凋亡、铁凋亡以及最近的热凋亡而死亡。后一种细胞死亡的特点是依赖于 Caspase 的 gasdermin 分裂成 C 端和 N 端片段,并在质膜上形成孔。气孔可在亚溶解阶段释放钾、白细胞介素-1β(IL-1β)、IL-18 和其他小分子,这可能是气孔在某些细胞类型(如炎症细胞)中的主要功能。另外,这一过程也可能发展为细胞的完全裂解(热解),并释放出大量细胞内容物。本综述讨论了参与 APAP 肝毒性的裂解过程的实验证据,以及反对将裂解作为 APAP 诱导肝细胞死亡的相关机制的论据。根据对现有文献的批判性评估和对病理生理学的理解,可以得出结论:热昏迷细胞死亡不太可能是 APAP 诱导肝损伤的相关因素。
{"title":"Role of Pyroptosis in Acetaminophen-Induced Hepatotoxicity.","authors":"Hartmut Jaeschke, David S Umbaugh, Anup Ramachandran","doi":"10.3390/livers2040032","DOIUrl":"10.3390/livers2040032","url":null,"abstract":"<p><p>Acetaminophen (APAP) is a widely used pain reliever that can cause liver injury or liver failure in response to an overdose. Understanding the mechanisms of APAP-induced cell death is critical for identifying new therapeutic targets. In this respect it was hypothesized that hepatocytes die by oncotic necrosis, apoptosis, necroptosis, ferroptosis and more recently pyroptosis. The latter cell death is characterized by caspase-dependent gasdermin cleavage into a C-terminal and an N-terminal fragment, which forms pores in the plasma membrane. The gasdermin pores can release potassium, interleukin-1β (IL-1β), IL-18, and other small molecules in a sublytic phase, which can be the main function of the pores in certain cell types such as inflammatory cells. Alternatively, the process can progress to full lysis of the cell (pyroptosis) with extensive cell contents release. This review discusses the experimental evidence for the involvement of pyroptosis in APAP hepatotoxicity as well as the arguments against pyroptosis as a relevant mechanism of APAP-induced cell death in hepatocytes. Based on the critical evaluation of the currently available literature and understanding of the pathophysiology, it can be concluded that pyroptotic cell death is unlikely to be a relevant contributor to APAP-induced liver injury.</p>","PeriodicalId":74083,"journal":{"name":"Livers","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10480188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preclinical Experience of the Mayo Spheroid Reservoir Bioartificial Liver (SRBAL) in Management of Acute Liver Failure Mayo球形贮存器生物人工肝(SRBAL)治疗急性肝功能衰竭的临床前经验
Pub Date : 2022-11-02 DOI: 10.3390/livers2040029
P. Felgendreff, Mohammad Tharwat, Seyed M. Hosseiniasl, B. Amiot, Anna Minshew, A. A. Rmilah, Xiaoye Sun, Dustin J. Duffy, W. Kremers, S. Nyberg
The Spheroid Reservoir Bioartificial Liver (SRBAL) is an innovative treatment option for acute liver failure (ALF). This extracorporeal support device, which provides detoxification and other liver functions using high-density culture of porcine hepatocyte spheroids, has been reported in three randomized large animal studies. A meta-analysis of these three preclinical studies was performed to establish efficacy of SRBAL treatment in terms of survival benefit and neuroprotective effect. The studies included two hepatotoxic drug models of ALF (D-galactosamine, α-amanitin/lipopolysaccharide) or a liver resection model (85% hepatectomy) in pigs or monkeys. The SRBAL treatment was started in three different settings starting at 12 h, 24 h or 48 h after induction of ALF; comparisons were made with two similar control groups in each model. SRBAL therapy was associated with significant survival and neuroprotective benefits in all three animal models of ALF. The benefits of therapy were dose dependent with the most effective configuration of SRBAL being continuous treatment of 24 h duration and dose of 200 g of porcine hepatic spheroids. Future clinical testing of SRBAL in patients with ALF appears warranted.
球形储层生物人工肝(SRBAL)是一种治疗急性肝衰竭(ALF)的创新选择。这种体外支持装置,通过高密度培养猪肝细胞球体提供解毒和其他肝脏功能,已在三个随机大型动物研究中报道。对这三项临床前研究进行荟萃分析,以确定SRBAL治疗在生存获益和神经保护作用方面的有效性。研究包括猪或猴子的两种肝毒性药物ALF (d -半乳糖胺,α-amanitin/脂多糖)模型和肝切除模型(85%肝切除)。SRBAL处理在ALF诱导后12小时、24小时和48小时三种不同的情况下开始;每个模型与两个相似的对照组进行比较。在所有三种ALF动物模型中,SRBAL治疗均与显著的生存和神经保护益处相关。治疗的益处是剂量依赖性的,SRBAL最有效的配置是持续治疗24小时,剂量为200 g猪肝球。SRBAL在ALF患者中的未来临床试验似乎是有必要的。
{"title":"Preclinical Experience of the Mayo Spheroid Reservoir Bioartificial Liver (SRBAL) in Management of Acute Liver Failure","authors":"P. Felgendreff, Mohammad Tharwat, Seyed M. Hosseiniasl, B. Amiot, Anna Minshew, A. A. Rmilah, Xiaoye Sun, Dustin J. Duffy, W. Kremers, S. Nyberg","doi":"10.3390/livers2040029","DOIUrl":"https://doi.org/10.3390/livers2040029","url":null,"abstract":"The Spheroid Reservoir Bioartificial Liver (SRBAL) is an innovative treatment option for acute liver failure (ALF). This extracorporeal support device, which provides detoxification and other liver functions using high-density culture of porcine hepatocyte spheroids, has been reported in three randomized large animal studies. A meta-analysis of these three preclinical studies was performed to establish efficacy of SRBAL treatment in terms of survival benefit and neuroprotective effect. The studies included two hepatotoxic drug models of ALF (D-galactosamine, α-amanitin/lipopolysaccharide) or a liver resection model (85% hepatectomy) in pigs or monkeys. The SRBAL treatment was started in three different settings starting at 12 h, 24 h or 48 h after induction of ALF; comparisons were made with two similar control groups in each model. SRBAL therapy was associated with significant survival and neuroprotective benefits in all three animal models of ALF. The benefits of therapy were dose dependent with the most effective configuration of SRBAL being continuous treatment of 24 h duration and dose of 200 g of porcine hepatic spheroids. Future clinical testing of SRBAL in patients with ALF appears warranted.","PeriodicalId":74083,"journal":{"name":"Livers","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44158276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Livers
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1